# Cencora, Inc.: Form 10-Q for the period ended Jun 30, 2021

- Company: [Cencora, Inc.](/companies/cor.md) (CIK 1140859)
- Form: 10-Q
- Filed: 2021-08-04
- Accepted by EDGAR: Aug 4, 2021, 16:11 ET
- Period: 2021-06-30
- Accession: 0001140859-21-000045
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1140859/000114085921000045/abc-20210630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1140859/000114085921000045/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-04-01 to 2021-06-30 | $53.41bn | us-gaap:Revenues |
| Revenue | 9 months, 2020-10-01 to 2021-06-30 | $155.08bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2021-04-01 to 2021-06-30 | $51.52bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2020-10-01 to 2021-06-30 | $150.20bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2021-04-01 to 2021-06-30 | $1.89bn | us-gaap:GrossProfit |
| Gross profit | 9 months, 2020-10-01 to 2021-06-30 | $4.87bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2021-04-01 to 2021-06-30 | $913.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2020-10-01 to 2021-06-30 | $2.38bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-04-01 to 2021-06-30 | $620.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-10-01 to 2021-06-30 | $1.79bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2021-04-01 to 2021-06-30 | $278.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2020-10-01 to 2021-06-30 | $559.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-04-01 to 2021-06-30 | $292.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-10-01 to 2021-06-30 | $1.10bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-04-01 to 2021-06-30 | $1.40 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2020-10-01 to 2021-06-30 | $5.31 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-04-01 to 2021-06-30 | $1.42 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2020-10-01 to 2021-06-30 | $5.37 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-04-01 to 2021-06-30 | 208,912,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2020-10-01 to 2021-06-30 | 207,679,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2020-10-01 to 2021-06-30 | $1.66bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2020-10-01 to 2021-06-30 | $273.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2020-10-01 to 2021-06-30 | $274.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2020-10-01 to 2021-06-30 | $82.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2021-06-30 | $2.55bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-06-30 | $37.26bn | us-gaap:AssetsCurrent |
| Total assets | at 2021-06-30 | $55.93bn | us-gaap:Assets |
| Current liabilities | at 2021-06-30 | $39.59bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2021-06-30 | $6.65bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2021-06-30 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2021-06-30 | $38.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 56,360 characters.

### Overview

The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein and in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2020.

We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. We are organized based upon the products and services we provide to our customers. Our operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant enough to require separate reportable segment disclosure, and, therefore, have been included in Other for the purpose of our reportable segment presentation.

### Pharmaceutical Distribution Services Segment

The Pharmaceutical Distribution Services reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. Through a number of operating businesses, the Pharmaceutical Distribution Services reportable segment provides pharmaceutical distribution (including plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the Pharmaceutical Distribution Services reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The Pharmaceutical Distribution Services reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, it delivers packaging solutions to institutional and retail healthcare providers.

### Other

Other consists of operating segments that focus on global commercialization services, animal health (MWI Animal Health or "MWI"), and international pharmaceutical wholesale and related service operations (Alliance Healthcare). The operating segments that focus on global commercialization services include AmerisourceBergen Consulting Services ("ABCS") and World Courier.

Alliance Healthcare supplies pharmaceuticals, other healthcare products, and related services to healthcare providers, including pharmacies, doctors, health centers and hospitals in 10 countries, primarily in Europe. MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Additionally, MWI offers demand-creating sales force services to manufacturers. ABCS, through a number of operating businesses, provides a full suite of integrated manufacturer services that range from clinical trial support to product post-approval and commercialization support. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry.

### Recent Developments

### Alliance Healthcare Acquisition

On June 1, 2021, we acquired a majority of Walgreens Boots Alliance, Inc.'s ("WBA") Alliance Healthcare businesses ("Alliance Healthcare") for $6,602.0 million in cash, subject to certain purchase price adjustments, $229.1 million of our common stock (2 million shares at the Company's June 1, 2021 opening stock price of $114.54 per share), $118.2 million of estimated accrued consideration, and $6.1 million of other equity consideration (the "Transaction") The net cash payment was $5,536.7 million, as we acquired $922.0 million of cash and cash equivalents and $143.3 million of restricted cash. (see Note 2 of the Notes to Consolidated Financial Statements for the preliminary allocation of the purchase price). The shares issued were from our treasury stock on a first-in, first-out basis and were originally purchased for $149.1 million. WBA’s operations in China, Italy, and Germany were not part of this Transaction. We funded the cash purchase price through a combination of cash on hand and new debt financing (see Note 6 of the Notes to Consolidated Financial Statements). The acquisition expands our reach and solutions in pharmaceutical distribution and adds to our depth and breadth of global manufacturer services.

### Other Strategic Transactions with Walgreens

In addition, we agreed to a three-year extension of our existing pharmaceutical distribution agreement with WBA and the arrangement pursuant to which we have access to generic drugs and related pharmaceutical products through Walgreens Boots Alliance Development GmbH (both through 2029), as well as a distribution agreement pursuant to which we will supply branded and generic pharmaceutical products to WBA’s Boots UK Ltd. subsidiary (through 2031). In January 2021, we also entered into an agreement with WBA to explore a series of strategic initiatives designed to create incremental growth and efficiencies in sourcing, logistics, and distribution.

See Part II. Other Information-Item 1A. Risk Factors on page 38 of this Quarterly Report on Form 10-Q for additional risk factors related to our strategic transactions with WBA.

### Opioid Litigation

On July 21, 2021, it was announced that we and the two other national pharmaceutical distributors have negotiated a comprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial majority of opioid lawsuits filed by state and local governmental entities (see Note 10 of the Notes to Consolidated Financial Statements).

### Executive Summary

This executive summary provides highlights from the results of operations that follow:

- Revenue increased by 17.7% and 10.3% from the prior year quarter and nine-month period, respectively, primarily due to the revenue growth in our Pharmaceutical Distribution Services segment and our June 2021 acquisition of Alliance Healthcare. The Pharmaceutical Distribution Services segment grew its revenue 13.2% and 8.7% from the prior year quarter and nine-month period, respectively, primarily due to increased sales of specialty products (which generally have higher selling prices), including COVID-19 treatments and overall market growth principally driven by unit volume growth. In addition, due to the onset of COVID-19 in March 2020, many of our customers increased their purchases in the fiscal quarter ended March 31, 2020, which resulted in fewer purchases in the quarter ended June 30, 2020. Revenue in Other increased 128.0% and 49.5% from the prior year quarter and nine-month period, respectively, primarily due to the June 2021 acquisition of Alliance Healthcare;
- Total gross profit increased 54.0%, from the prior year quarter and 26.8%, from the prior nine-month period. Gross profit was favorably impacted by increases of gross profit in Pharmaceutical Distribution Services of 16.2% from the prior year quarter and 12.7% from the prior year nine-month period, increases in gross profit in Other of 74.7% from the prior year quarter and 30.4% from the prior year nine-month period, respectively, last-in, first-out ("LIFO") credits in the current year periods in comparison to a LIFO expense in the prior year periods, and increases in gains from antitrust litigation settlements Pharmaceutical Distribution Services' gross profit increased from the prior year periods primarily due to revenue growth, including an increase in specialty product sales. Gross profit in Other increased from the prior year quarter and nine-month period primarily due to the June 2021 acquisition of Alliance Healthcare and revenue growth at World Courier and MWI;
- Distribution, selling, and administrative expenses increased 37.0% compared to the prior year quarter and 16.2% compared to the prior nine-month period primarily due to the June 2021 acquisition of Alliance Healthcare and increases in payroll-related operating costs to support current and future revenue growth. Total operating expenses increased by 54.4%, from the prior year quarter and 7.5%, from the prior year nine-month period primarily due to the June 2021 acquisition of Alliance Healthcare, an increase in legal accruals primarily related to our proposed opioid settlement, and an increase in acquisition-related deal and integration costs;
- Operating income increased by 53.3%, from the prior year quarter and 83.3%, from the prior year nine-month period due to the increases in total gross profit and offset in part by increases in total operating expenses; and
- Our effective tax rates were 48.5% and 33.6% for the three and nine months ended June 30, 2021, respectively. The effective tax rates for the three and nine months ended June 30, 2021 were higher than the U.S. statutory rate primarily due to U.K. Tax Reform (see Note 4 of the Notes to Consolidated Financial Statements).

### Results of Operations

### Revenue

*(dollars in thousands)*

|  | Three months ended June 30, 2021 | 2020 | Change | Nine months ended June 30, 2021 | 2020 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pharmaceutical Distribution Services | $49,312,013 | $43,579,119 | 13.2% | $146,905,854 | $135,178,617 | 8.7% |
| Other: |  |  |  |  |  |  |
| MWI Animal Health | 1,193,530 | 1,008,581 | 18.3% | 3,442,494 | 3,079,915 | 11.8% |
| Alliance Healthcare | 1,924,858 | — |  | 1,924,858 | — |  |
| Global Commercialization Services | 1,009,878 | 801,952 | 25.9% | 2,905,960 | 2,454,195 | 18.4% |
| Total Other | 4,128,266 | 1,810,533 | 128.0% | 8,273,312 | 5,534,110 | 49.5% |
| Intersegment eliminations | (34,584) | (22,875) |  | (102,744) | (63,569) |  |
| Revenue | $53,405,695 | $45,366,777 | 17.7% | $155,076,422 | $140,649,158 | 10.3% |

We now expect our revenue growth percentage to be in the low-double digits in fiscal 2021 due to the addition of Alliance Healthcare in June 2021. Our future revenue growth will continue to be affected by various factors, such as industry growth trends, including drug utilization, the introduction of new, innovative brand therapies, the likely increase in the number of generic drugs and biosimilars that will be available over the next few years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers and the rate of conversion from brand products to those generic drugs and biosimilars, price inflation and price deflation, general economic conditions in the United States, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third-party reimbursement rates to our customers, changes in government rules and regulations, and the impact of the COVID-19 pandemic.

Revenue increased by 17.7% and 10.3% from the prior year quarter and nine-month period, respectively, primarily due to the revenue growth in our Pharmaceutical Distribution Services segment and our June 2021 acquisition of Alliance Healthcare.

The Pharmaceutical Distribution Services segment grew its revenue by 13.2%, or $5.7 billion, from the prior year quarter and 8.7%, or $11.7 billion, from the prior year nine-month period primarily due to increased sales of specialty products (which generally have higher selling prices), including COVID-19 treatments and overall market growth principally driven by unit volume growth. In addition, due to the onset of COVID-19 in March 2020, many of our customers increased their purchases in the fiscal quarter ended March 31, 2020, which resulted in fewer purchases in the quarter ended June 30, 2020.

More specifically, the increase in the Pharmaceutical Distribution Services segment revenue was largely attributable to the following (in billions):

|  | Three-month Period | Nine-month Period |
| --- | ---: | ---: |
| Increased sales to Walgreens, our largest customer | $1.1 | $1.7 |
| Increased sales to specialty physician practices | $0.9 | $1.8 |
| Increased sales to other customers, including COVID-19 treatments | $3.7 | $8.2 |

Revenue in Other increased 128.0%, or $2.3 billion, from the prior year quarter and 49.5%, or $2.7 billion, from the prior year nine-month period primarily due to the June 2021 acquisition of Alliance Healthcare and due to growth in the other operating segments: MWI, ABCS, and World Courier.

A number of our contracts with customers, including group purchasing organizations, are typically subject to expiration each year. We may lose a significant customer if an existing contract with such customer expires without being extended, renewed, or replaced. During the nine months ended June 30, 2021, no significant contracts expired. Over the next twelve months, there are no significant contracts scheduled to expire. Additionally, from time to time, significant contracts may be terminated in accordance with their terms or extended, renewed, or replaced prior to their expiration dates. If those contracts are extended, renewed, or replaced at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.

### Gross Profit

*(dollars in thousands)*

|  | Three months ended June 30, 2021 | 2020 | Change | Nine months ended June 30, 2021 | 2020 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pharmaceutical Distribution Services | $1,053,776 | $906,663 | 16.2% | $3,218,142 | $2,856,715 | 12.7% |
| Other | 574,794 | 328,942 | 74.7% | 1,355,849 | 1,039,502 | 30.4% |
| Intersegment eliminations | (1,716) | (3,396) |  | (8,171) | (3,975) |  |
| Gains from antitrust litigation settlements | 147,432 | — |  | 147,432 | 8,546 |  |
| LIFO credit (expense) | 113,920 | (6,061) |  | 160,565 | (43,195) |  |
| PharMEDium remediation costs | — | — |  | — | (7,135) |  |
| PharMEDium shutdown costs | — | (432) |  | — | (5,421) |  |
| Gross profit | $1,888,206 | $1,225,716 | 54.0% | $4,873,817 | $3,845,037 | 26.8% |

Gross profit increased 54.0%, or $662.5 million, from the prior year quarter and 26.8%, or $1,028.8 million, from the prior year nine-month period. Gross profit in the current year periods was favorably impacted by increases in gross profit in Pharmaceutical Distribution Services and Other, a LIFO credit in the current year periods in comparison to a LIFO expense in the prior year periods, and increases in gains from antitrust litigation settlements.

Pharmaceutical Distribution Services' gross profit increased 16.2%, or $147.1 million, from the prior year quarter and 12.7%, or $361.4 million, from the prior year nine-month period primarily due to revenue growth, including an increase in specialty product sales. As a percentage of revenue, Pharmaceutical Distribution Services' gross profit margin was 2.14% and 2.19% in the current year quarter and nine-month period, respectively, a 6-basis point increase from the prior year quarter and an 8-basis point increase from the prior year nine-month period primarily due to increases in specialty product sales.

Gross profit in Other increased 74.7%, or $245.9 million from the prior year quarter and 30.4%, or $316.3 million, from the prior year nine-month period primarily due to the June 2021 acquisition of Alliance Healthcare and revenue growth at World Courier and MWI. As a percentage of revenue, gross profit margin in Other of 13.92% in the current year quarter decreased from 18.17% in the prior year quarter. As a percentage of revenue, gross profit margin in Other of 16.39% in the current year nine-month period decreased from 18.78% in the prior year nine-month period. The declines in gross profit margins in the current year periods were primarily due to the June 2021 acquisition of Alliance Healthcare, which has lower gross profit margins than the other operating segments within Other.

We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $147.4 million in the three and nine months ended June 30, 2021. We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $8.5 million in the nine months ended June 30, 2020. The gains were recorded as reductions to Cost of Goods Sold (see Note 11 of the Notes to Consolidated Financial Statements).

Our cost of goods sold for interim periods includes a LIFO provision that is recorded ratably on a quarterly basis and is based on our estimated annual LIFO provision. The annual LIFO provision, which we estimate on a quarterly basis, is affected by manufacturer pricing practices, which may be impacted by market and other external influences, expected changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors may have a material impact to our annual LIFO provision. The LIFO credit in the three and nine months ended June 30, 2021 is largely being driven by an increase in generic pharmaceutical deflation.

### Operating Expenses

*(dollars in thousands)*

|  | Three months ended June 30, 2021 | 2020 | Change | Nine months ended June 30, 2021 | 2020 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Distribution, selling, and administrative | $913,414 | $666,885 | 37.0% | $2,378,563 | $2,046,251 | 16.2% |
| Depreciation and amortization | 127,101 | 95,415 | 33.2% | 327,451 | 293,725 | 11.5% |
| Employee severance, litigation, and other | 226,964 | 58,585 |  | 375,501 | 165,626 |  |
| Impairment of PharMEDium assets | — | — |  | — | 361,652 |  |
| Total operating expenses | $1,267,479 | $820,885 | 54.4% | $3,081,515 | $2,867,254 | 7.5% |

Distribution, selling, and administrative expenses increased 37.0%, or $246.5 million, compared to the prior year quarter and 16.2%, or $332.3 million, compared to the prior year nine-month period primarily due to the June 2021 acquisition of Alliance Healthcare and increases in payroll-related operating costs to support current and future revenue growth. As a percentage of revenue, distribution, selling, and administrative expenses were 1.71% and 1.53% in the current year quarter and nine-month period, respectively, a 24-basis point increase compared to prior year quarter and an 8-basis point increase compared to the prior year nine-month period. The increases in distribution, selling, and administrative expenses as a percentage of revenue were primarily due to the June 2021 acquisition of Alliance Healthcare.

Depreciation expense increased 18.3% and 11.0% from the prior year quarter and nine-month period, respectively, primarily due to an increase in capital projects being depreciated and depreciation of property and equipment originating from the June 2021 acquisition of Alliance Healthcare. Amortization expense increased 73.4% compared to the prior year quarter and increased 12.7% from the prior year nine-month period primarily due to amortization of intangible assets originating from the June 2021 acquisition of Alliance Healthcare. The current year nine-month period increase in amortization expense from the Alliance Healthcare acquisition was offset in part by the fiscal 2020 impairments of PharMEDium intangible assets.

Employee severance, litigation, and other in the three months ended June 30, 2021 included $28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, a $124.3 million accrual related to our proposed opioid settlement, $54.7 million of acquisition-related deal and integration costs primarily related to the June 2021 acquisition Alliance Healthcare, $14.7 million related to our business transformation efforts, and $4.4 million of severance and other restructuring initiatives. Employee severance, litigation, and other in the three months ended June 30, 2020 included $31.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, $9.4 million related to our business transformation efforts, $8.3 million of acquisition-related deal and integration costs, $6.5 million of severance costs primarily related to position eliminations resulting from our decision to permanently exit the PharMEDium compounding business, and $2.9 million of other restructuring initiatives.

Employee severance, litigation, and other in the nine months ended June 30, 2021 included $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, a $141.4 million accrual related to our proposed opioid settlement, $97.1 million of acquisition-related deal and integration costs primarily related to the June 2021 acquisition of Alliance Healthcare, $37.7 million related to our business transformation efforts, $6.7 million of severance costs, and $6.6 million of other restructuring initiatives. Employee severance, litigation, and other in the nine months ended June 30, 2020 included $86.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, $32.4 million of severance costs primarily related to position eliminations resulting from our decision to permanently exit the PharMEDium compounding business, $26.9 million related to our business transformation efforts, $10.4 million of other restructuring initiatives, and $9.1 million of acquisition-related deal and integration costs.

### Operating Income

*(dollars in thousands)*

|  | Three months ended June 30, 2021 | 2020 | Change | Nine months ended June 30, 2021 | 2020 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pharmaceutical Distribution Services | $483,914 | $426,643 | 13.4% | $1,569,014 | $1,381,434 | 13.6% |
| Other | 146,869 | 82,875 | 77.2% | 391,696 | 295,614 | 32.5% |
| Intersegment eliminations | (162) | (1,996) |  | (6,615) | (2,575) |  |
| Total segment operating income | 630,621 | 507,522 | 24.3% | 1,954,095 | 1,674,473 | 16.7% |
| Gains from antitrust litigation settlements | 147,432 | — |  | 147,432 | 8,546 |  |
| LIFO credit (expense) | 113,920 | (6,061) |  | 160,565 | (43,195) |  |
| PharMEDium remediation costs | — | — |  | — | (16,165) |  |
| PharMEDium shutdown costs | — | (12,936) |  | — | (45,406) |  |
| Contingent consideration adjustment | — | — |  | — | 12,153 |  |
| Acquisition-related intangibles amortization | (44,282) | (25,109) |  | (94,289) | (85,345) |  |
| Employee severance, litigation, and other | (226,964) | (58,585) |  | (375,501) | (165,626) |  |
| Impairment of PharMEDium assets | — | — |  | — | (361,652) |  |
| Operating income | $620,727 | $404,831 | 53.3% | $1,792,302 | $977,783 | 83.3% |

Segment operating income is evaluated before gains from antitrust litigation settlements; LIFO credit (expense); PharMEDium remediation costs; PharMEDium shutdown costs; contingent consideration adjustment; acquisition-related intangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets.

Pharmaceutical Distribution Services' operating income increased 13.4%, or $57.3 million, from the prior year quarter and 13.6%, or $187.6 million, from the prior year nine-month period primarily due to the increases in gross profit, as noted above, and were offset in part by increases in operating expenses. As a percentage of revenue, Pharmaceutical Distribution Services' operating income margins were 0.98% and 1.07% in the quarter and nine-month period ended June 30, 2021, respectively, and was flat compared to the prior year quarter and represented an increase of 5 basis points compared to the prior year nine-month period. The increase from the prior year nine-month period was primarily due to the increase in specialty product sales, including COVID-19 treatments.

Operating income in Other increased 77.2%, or $64.0 million, from the prior quarter and 32.5%, or $96.1 million, from the prior year nine-month period primarily due to the June 2021 acquisition of Alliance Healthcare and due to the increases in operating income at MWI and World Courier.

Interest expense, net and the respective weighted average interest rates in the three months ended June 30, 2021 and 2020 were as follows:

*(dollars in thousands)*

|  | 2021 Amount | Weighted Average Interest Rate | 2020 Amount | Weighted Average Interest Rate |
| --- | ---: | ---: | ---: | ---: |
| Interest expense | $53,011 | 2.78% | 39,177 | 3.33% |
| Interest income | (1,673) | 0.16% | (1,429) | 0.21% |
| Interest expense, net | $51,338 |  | 37,748 |  |

Interest expense, net and the respective weighted average interest rates in the nine months ended June 30, 2021 and 2020 were as follows:

*(dollars in thousands)*

|  | 2021 Amount | Weighted Average Interest Rate | 2020 Amount | Weighted Average Interest Rate |
| --- | ---: | ---: | ---: | ---: |
| Interest expense | $122,773 | 2.98% | $122,761 | 3.50% |
| Interest income | (3,295) | 0.13% | (19,585) | 0.92% |
| Interest expense, net | $119,478 |  | $103,176 |  |

Interest expense, net increased 36.0%, or $13.6 million, from prior year quarter, and 15.8%, or $16.3 million, from the prior year nine-month period. Interest expense, net increased in the three months ended June 30, 2021 primarily due to the issuance of our $1,525 million of 0.737% senior notes and $1,000 million of 2.700% senior notes in March 2021 and the $500 million variable-rate term loan that was issued in June 2021, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare. Interest expense, net in the nine-month period ended June 30, 2021 increased primarily due to a decrease in interest income resulting from a decrease in investment interest rates. The increase in interest expense as a result of the above-mentioned debt issuances in the nine-month period ended June 30, 2021 was offset by a lower weighted-average borrowing interest rate and the repayment of our $400 million term loan upon its maturity in October 2020.

Our effective tax rates were 48.5% and 33.6% for the three and nine months ended June 30, 2021, respectively. Our effective tax rates were 16.5% and (70.1)% for the three and nine months ended June 30, 2020, respectively. The effective tax rates for the three and nine months ended June 30, 2021 were higher than the U.S. statutory rate primarily due to U.K. Tax Reform (see Note 4 of the Notes to Consolidated Financial Statements). The effective tax rates for the three and nine months ended June 30, 2020 were lower than the U.S. statutory rate due to the tax benefits associated with the worthless stock deduction in connection with the permanent shutdown of the PharMEDium compounding business and the Coronavirus Aid, Relief, and Economic Security Act (the provisions of which adjusted the net operating loss carryback rules and accelerated available refunds for alternative minimum tax credit carryforwards) and a higher mix of foreign earnings at lower tax rates in Switzerland and Ireland since U.S. earnings were lower principally due to the impairments of PharMEDium assets.

### Liquidity and Capital Resources

The following table illustrates our debt structure as of June 30, 2021, including availability under the multi-currency revolving credit facility, the receivables securitization facility, the revolving credit note, 364-day revolving credit facility, the Alliance Healthcare debt, and the overdraft facility,

*(in thousands)*

| Fixed-Rate Debt: | Outstanding Balance | Additional Availability |
| --- | ---: | ---: |
| $1,525,000, 0.737% senior notes due 2023 | $1,517,263 | $— |
| $500,000, 3.400% senior notes due 2024 | 498,600 | — |
| $500,000, 3.250% senior notes due 2025 | 497,499 | — |
| $750,000, 3.450% senior notes due 2027 | 744,571 | — |
| $500,000, 2.800% senior notes due 2030 | 494,585 | — |
| $1,000,000, 2.700% senior notes due 2031 | 989,275 | — |
| $500,000, 4.250% senior notes due 2045 | 494,892 | — |
| $500,000, 4.300% senior notes due 2047 | 492,955 | — |
| Nonrecourse debt | 60,615 | — |
| Total fixed-rate debt | 5,790,255 | — |
| **Variable-Rate Debt:** |  |  |
| Revolving credit note | — | 75,000 |
| Receivables securitization facility due 2022 | 350,000 | 1,100,000 |
| 364-day revolving credit facility | — | 1,000,000 |
| Term loan due in June 2023 | 499,661 | — |
| Overdraft facility due 2024 (£10,000) | — | 13,833 |
| Multi-currency revolving credit facility due 2024 | — | 1,400,000 |
| Alliance Healthcare debt | 354,975 | 341,005 |
| Nonrecourse debt | 107,901 | — |
| Total variable-rate debt | 1,312,537 | 3,929,838 |
| Total debt | $7,102,792 | $3,929,838 |

Our operating results have generated cash flows, which, together with availability under our debt agreements and credit terms from suppliers, have provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and purchases of shares of our common stock.

Our primary ongoing cash requirements will be to finance working capital, fund the repayment of debt, fund the payment of interest on debt, fund purchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities. Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements, including the opioid litigation payments that are expected to be made over 18 years (see below).

As discussed in Note 10 of the Notes to Consolidated Financial Statements, in the fourth quarter of fiscal 2020, with regard to litigation relating to the distribution of prescription opioid pain medications, we recorded a $6.6 billion liability ($5.5 billion, net of income tax benefit). On July 21, 2021, it was announced that we and the two other national pharmaceutical distributors have negotiated a comprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial majority of opioid lawsuits filed by state and local governmental entities. The proposed settlement agreement includes a cash component, pursuant to which we would pay up to approximately $6.4 billion over 18 years, including a $443.0 million payment that is expected to be made into escrow prior to September 30, 2021, and the payment will be disbursed after the distributors have determined that there is sufficient participation to proceed, or returned to us if the settlement does not become effective. The aforementioned litigation liability has not and is not expected to have an impact on our compliance with our debt covenants or our ability to pay dividends.

As of June 30, 2021 and September 30, 2020, our cash and cash equivalents held by foreign subsidiaries were $1,348.6 million and $675.9 million, respectively. We have the ability to repatriate the majority of our cash and cash equivalents held by our foreign subsidiaries without incurring significant additional taxes upon repatriation.

We have increased seasonal needs related to our inventory build during the December and March quarters that, depending on our cash balance, may require the use of our credit facilities to fund short-term capital needs. Our cash balances in the nine months ended June 30, 2021 and 2020 were supplemented by intra-period credit facility borrowings to cover short-term working capital needs. The largest amount of intra-period borrowings under our revolving and securitization credit facilities that was outstanding at any one time during the nine months ended June 30, 2021 and 2020 was $637.7 million and $39.6 million, respectively. We had $4,612.4 million and $117.4 million of cumulative intra-period borrowings that were repaid under our credit facilities during the nine months ended June 30, 2021 and 2020, respectively.

We have a $1.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility"), which is scheduled to expire in September 2024, with a syndicate of lenders. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based on our debt rating and ranges from 70 basis points to 112.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (101.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of June 30, 2021) and from 0 basis points to 12.5 basis points over the alternate base rate and Canadian prime rate, as applicable. We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on our debt rating, ranging from 5 basis points to 12.5 basis points, annually, of the total commitment (11 basis points as of June 30, 2021). We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we were compliant as of June 30, 2021.

We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase our borrowing capacity as it is fully backed by our Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under our commercial paper program as of June 30, 2021.

We have a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which is scheduled to expire in September 2022. We have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR plus a program fee. We pay a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of June 30, 2021.

In February 2021, we entered into an agreement pursuant to which we obtained a $1.0 billion senior secured revolving credit facility ("364-Day Revolving Credit Facility") with a syndicate of lenders, which is scheduled to expire 364 days after June 1, 2021, the closing of the acquisition of a majority of WBA's Alliance Healthcare businesses. Interest on borrowings under the 364-Day Revolving Credit Facility accrues at specified rates based on our debt rating and ranges from 83.5 basis points to 125 basis points (104.5 basis points as of June 30, 2021) over LIBOR and from 0 basis points to 25 basis points (4.5 basis points as of June 30, 2021) over the alternate base rate. We pay facility fees to maintain availability under the 364-Day Revolving Credit Facility at specified rates based on its debt rating, ranging from 4 basis points to 12.5 basis points (8 basis points as of June 30, 2021), annually, of the total commitment. We may choose to repay or reduce our commitments under the 364-Day Revolving Credit Facility at any time. The 364-Day Revolving Credit Facility contains a feature whereby we have the option to convert to a term loan the outstanding borrowings under this facility. The 364-Day Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we were compliant as of June 30, 2021.

We have an uncommitted, unsecured line of credit available to us pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice. We also have an uncommitted U.K. overdraft facility ("Overdraft Facility") to fund short-term normal trading cycle fluctuations related to its MWI business. In February 2021, we extended the Overdraft Facility to February 2024 and reduced the borrowing capacity from £30 million to £10 million.

Our $400 million Term Loan matured and was repaid in October 2020.

In February 2021, we entered into a $1.0 billion variable-rate term loan (“February 2021 Term Loan”), which was available to be drawn on the closing date of the acquisition of a majority of WBA's Alliance Healthcare businesses. In April 2021, we reduced our commitment under the February 2021 Term Loan to $500 million. In June 2021, we borrowed $500 million under the February 2021 Term Loan to finance a portion of the Alliance Healthcare acquisition. The February 2021 Term Loan matures in June 2023. The February 2021 Term Loan bears interest at a rate equal either to a base rate plus a margin, or LIBOR, plus a margin. The margin is based on the public debt ratings of us and ranges from 87.5 basis points to 137.5 basis points (112.5 basis points as of June 30, 2021) over LIBOR and 0 basis points to 37.5 basis points (12.5 basis points as of June 30, 2021) over a base rate. The February 2021 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of June 30, 2021.

In March 2021, we issued $1,525 million of 0.737% senior notes due March 15, 2023 (the "2023 Notes"). The 2023 Notes were sold at 100.00% of the principal amount. Interest on the 2023 Notes is payable semi-annually in arrears, commencing on September 15, 2021. In March 2021, we issued $1,000 million of 2.700% senior notes due March 15, 2031 (the "2031 Notes"). The 2031 Notes were sold at 99.79% of the principal amount and have an effective yield of 2.706%. Interest on the 2031 Notes is payable semi-annually in arrears, commencing on September 15, 2021. The 2023 Notes and 2031 Notes rank pari passu to our other senior notes, the Multi-Currency Revolving Credit Facility, the Revolving Credit Note, the Overdraft Facility, and the 364-Day Revolving Credit Facility. We used the proceeds from the 2023 Notes and 2031 Notes to finance a portion of the June 2021 Alliance Healthcare acquisition.

Alliance Healthcare debt is comprised of uncommitted revolving credit facilities in various currencies with various rates. These facilities are used to fund its working capital needs.

Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.

In October 2018, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion of outstanding shares of our common stock, subject to market conditions. During the nine months ended June 30, 2021, we purchased $55.5 million of our common stock to complete our authorization under this program.

In May 2020, our board of directors authorized a share repurchase program allowing us to purchase up to $500 million of our outstanding shares of common stock, subject to market conditions. During the nine months ended June 30, 2021, we purchased $26.6 million of our common stock. As of June 30, 2021, we had $473.4 million of availability remaining under this program.

We have market risk exposure to interest rate fluctuations relating to our debt. We manage interest rate risk by using a combination of fixed-rate and variable-rate debt. The amount of variable-rate debt fluctuates during the year based on our working capital requirements. We had $1,312.5 million of variable-rate debt outstanding as of June 30, 2021. We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates. However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us. There were no such financial instruments in effect as of June 30, 2021.

We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents. We had $2,553.2 million in cash and cash equivalents as of June 30, 2021. The unfavorable impact of a hypothetical decrease in interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt. For every $100 million of cash invested that is in excess of variable-rate debt, a 10-basis point decrease in interest rates would increase our annual net interest expense by $0.1 million.

We have exposure to foreign currency and exchange rate risk from our non-U.S. operations. Our largest exposure to foreign exchange rates exists primarily with the Euro, the U.K. Pound Sterling, the Turkish Lira, the Egyptian Pound, the Brazilian Real, and the Canadian Dollar. With the June 2021 acquisition of Alliance Healthcare, our foreign currency and exchange rate risk increased; therefore, we now use foreign currency denominated forward contracts to hedge against changes in foreign exchange rates. We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes. Revenue from our foreign operations during the nine-month period ended June 30, 2021 was less than four percent of our consolidated revenue and included one month of revenue from Alliance Healthcare. We expect revenue from foreign operations to increase in the future as Alliance Healthcare's revenue will comprise a larger portion of our total revenue.

The following is a summary of our contractual obligations for future principal and interest payments on our debt, minimum rental payments on our noncancellable operating leases, and minimum payments on our other commitments as of June 30, 2021:

| Payments Due by Period (in thousands) | Debt, Including Interest Payments | Operating Leases | Other Commitments | Total |
| --- | ---: | ---: | ---: | ---: |
| Within 1 year | $626,369 | $203,228 | $131,059 | $960,656 |
| 1-3 years | 3,232,975 | 343,375 | 195,203 | 3,771,553 |
| 4-5 years | 753,028 | 266,208 | 118,615 | 1,137,851 |
| After 5 years | 4,348,001 | 476,476 | — | 4,824,477 |
| Total | $8,960,373 | $1,289,287 | $444,877 | $10,694,537 |

The 2017 Tax Act requires a one-time transition tax to be recognized on historical foreign earnings and profits. We expect to pay $175.6 million, net of overpayments and tax credits, related to the transition tax as of June 30, 2021, which is payable in installments over a six-year period, which commenced in January 2021. The transition tax commitment is included in "Other Commitments" in the above table.

Our liability for uncertain tax positions was $512.8 million (including interest and penalties) as of June 30, 2021. This liability represents an estimate of tax positions that we have taken in our tax returns which may ultimately not be sustained upon examination by taxing authorities. Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.

During the nine months ended June 30, 2021, our operating activities provided cash of $1,656.8 million in comparison to $907.8 million in the prior year period. Cash provided by operations during the nine months ended June 30, 2021 was principally the result of net income of $1,108.2 million and non-cash items of $600.0 million, an increase in accounts payable of $242.4 million, and a decrease in income taxes receivable of $234.4 million, offset in part by an increase in inventories of $594.7 million and an increase in accounts receivable of $116.8 million. Non-cash items were primarily comprised of the provision for deferred income taxes of $303.6 million, depreciation expense of $237.9 million, and amortization expense of $102.6 million. The increase in inventories reflects the increase in business volume.

During the nine months ended June 30, 2020, our operating activities provided cash of $907.8 million. Cash provided by operations during the nine months ended June 30, 2020 was principally the result of net income of $1,444.9 million, non-cash items of $822.0 million, and an increase in accounts payable of $824.1 million, offset in part by increases in inventories of $910.8 million, income taxes receivable of $590.2 million, and accounts receivable of $436.2 million. The non-cash items were comprised primarily of a $361.7 million impairment of PharMEDium's assets, $215.2 million of depreciation expense, and $93.8 million of amortization expense. The increase in accounts payable was primarily driven by the increase in our inventories and the timing of scheduled payments to suppliers. The increase in income taxes receivable was the result of a benefit recorded in connection with certain discrete items. The increase in accounts receivable was the result of the timing of payments from our customers.

We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance. The below financial metrics are calculated based upon a quarterly average and can be impacted by the timing of cash receipts and disbursements, which can vary significantly depending upon the day of the week on which the month ends.

|  | Three months ended June 30, 2021 | 2020 | Nine months ended June 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| Days sales outstanding | 25.2 | 25.8 | 25.6 | 24.8 |
| Days inventory on hand | 28.6 | 30.9 | 28.9 | 29.1 |
| Days payable outstanding | 57.4 | 59.4 | 58.0 | 57.9 |

Our cash flows from operating activities can vary significantly from period to period based upon fluctuations in our period-end working capital account balances. Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations. Operating cash flows during the nine months ended June 30, 2021 included $110.1 million of interest payments and $43.2 million of income tax payments, net of refunds. Operating cash flows during the nine months ended June 30, 2020 included $125.4 million of interest payments and $120.7 million of income tax payments, net of refunds.

Capital expenditures in the nine months ended June 30, 2021 and 2020 were $273.4 million and $251.1 million, respectively. Significant capital expenditures in the nine months ended June 30, 2021 and 2020 included costs associated with facility expansions, various technology initiatives, including costs related to enhancing and upgrading our primary information technology operating systems. We currently expect to invest approximately $400 million for capital expenditures during fiscal 2021.

Net cash used in investing activities in the nine months ended June 30, 2021 included $5,536.7 million for the June 2021 acquisition of Alliance Healthcare, net of cash acquired, and $162.6 million for equity investments.

Net cash provided by financing activities in the nine months ended June 30, 2021 principally resulted from the issuance of senior notes and the February 2021 Term Loan (see above) and $164.3 million of exercises of stock options, offset in part by the repayment of the $400 million Term Loan, $274.0 million in cash dividends paid on our common stock, and $82.2 million in purchases of our common stock. Net cash used in financing activities in the nine months ended June 30, 2020 principally resulted from $420.4 million in purchases of our common stock and $256.8 million in cash dividends paid on our common stock.

In November 2020, our board of directors increased the quarterly dividend paid on common stock by 5% from $0.42 per share to $0.44 per share. We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remains within the discretion of our board of directors and will depend upon future earnings, financial condition, capital requirements, and other factors.

### Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or costly than expected; the Company’s or Alliance Healthcare’s failure to achieve expected or targeted future financial and operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company’s operations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this report (including in Item 1A (Risk Factors)), (ii) in Item 1A (Risk Factors), in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (iii) in other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.

## Market risk

As filed, 262 characters.

The Company’s most significant market risks are the effects of changing interest rates, foreign currency risk, and changes in the price and volatility of the Company’s common stock. See the discussion under "Liquidity and Capital Resources" in Item 2 on page 31.

## Controls and procedures

As filed, 1,526 characters.

### Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are intended to ensure that information required to be disclosed in the Company’s reports submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also are intended to ensure that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

The Company’s Chief Executive Officer and Chief Financial Officer, with the participation of other members of the Company’s management, have evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a — 15(e) and 15d — 15(e) under the Exchange Act) and have concluded that the Company’s disclosure controls and procedures were effective for their intended purposes as of the end of the period covered by this report.

### Changes in Internal Control over Financial Reporting

During the third quarter of fiscal 2021, there was no change in AmerisourceBergen Corporation’s internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended June 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 2,377 characters.

Except as supplemented by the additional risk factors disclosed below, our significant business risks are described in Item 1A to Form 10-K for the fiscal year ended September 30, 2020 to which reference is made herein.

### Risks Related to Our Strategic Transactions with Walgreens Boots Alliance, Inc. ("WBA")

***The combined business may underperform our expectations or may cause our financial results to differ from those expectations.***

We believe that our acquisition of the majority of WBA's Alliance Healthcare businesses, as one of the largest pharmaceutical wholesalers in Europe, will extend our core wholesale, distribution and related solutions capabilities, enhance our existing global platform of manufacturer services, and further our ability to support global patient access to pharmaceutical products. However, our integration of the acquired Alliance Healthcare businesses may be more difficult, time consuming or costly than expected, especially with respect to initiatives related to enhancing and upgrading our information technology and security systems. We may also not be able to retain or integrate the Alliance Healthcare employees necessary to efficiently manage the combined company or we may suffer customer loss and business disruption. We may fail to achieve expected or targeted future financial and operating performance and results, and the combined company may fail to achieve expected benefits, synergies and operating efficiencies following the closing of the acquisition within the expected timeframes or at all.

The acquisition will expand our core wholesale and specialty distribution business from the US, Canada and Brazil to Europe and additional countries with the addition of Alliance Healthcare's wholesale and pre-wholesale business in 13 countries. These international operations may be adversely affected by laws and regulations reducing reimbursement rates for pharmaceuticals and/or medical treatments or services. In addition, we will encounter increased risks relating to compliance with domestic laws relating to foreign corrupt practices and foreign laws and regulations relating to labor and employment, pharmacy, licensing, tax, trade, intellectual property, privacy and data protection and other matters, and if we fail to comply with such laws and regulations, we could be subject to civil and criminal penalties.

Filed Aug 4, 2021.
Source: SEC EDGAR, the filing index for accession 0001140859-21-000045. Last ingested by Listed: Nov 15, 2026, 01:23 ET. No prices; not investment advice.
